EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study

Maria Fleseriu iD, Richard J Auchus iD, Wenyu Huang iD, Joanna L Spencer-Segal, Kevin C J Yuen, Kelley C Dacus, Julianne Padgett, Elizabeth K Babler, Ashis K Das, Cynthia Campos iD, Michael S Broder, Adriana G Ioachimescu

Journal of the Endocrine Society · 24.03.2025 · 9 (5)

DOI: 10.1210/jendso/bvaf046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 15.03.2025. Verfasst von Maria Fleseriu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Neurological Surgery, Pituitary Center, Oregon Health & Science University, Portland, OR 97239, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recordati Rare Diseases, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

In clinical trials, osilodrostat (11β-hydroxylase inhibitor) effectively reduced cortisol levels in patients with endogenous Cushing syndrome (CS).

Objectives

A real-world study (ILLUSTRATE) was conducted evaluating osilodrostat use in patients with various etiologies of CS in the United States.

Methods

A retrospective chart-review study was conducted of adults with CS treated with osilodrostat between May 1, 2020, and October 29, 2021.

Results

A total of 42 patients (Cushing disease, n = 34; CS due to adrenal adenoma, n = 5; ectopic adrenocorticotropin syndrome [EAS], n = 3) were included. Starting doses were 2 mg twice daily in 27/42 patients (64.3%), maintenance doses were 2 mg twice daily in 6 of 9 patients (66.7%) attaining them. During osilodrostat treatment, urinary free cortisol (UFC) decreased below the upper limit of normal (ULN) in 14 of 20 patients (70.0%) with pretreatment UFC greater than the ULN. Osilodrostat response was observed across a range of doses (2-20 mg/day). In Cushing disease, median UFC and late-night salivary cortisol decreased from 3.03 and 2.39 × ULN, respectively, to 0.71 and 1.13 × ULN at last assessment in those with available data (n = 17 and 8, respectively). UFC decreased in all patients with adrenal CS or EAS with available data (n = 2 each). There were no unexpected safety signals; the most common adverse events (incidence ≥20%) were fatigue, nausea, and lower-extremity edema. Glucocorticoid withdrawal syndrome and/or adrenal insufficiency were reported in 12 of 42 patients (28.6%) after osilodrostat initiation, resulting in treatment discontinuation in 4.

Conclusion

In routine practice with dosing individualized according to clinical condition, response, and tolerability, osilodrostat was effective and well tolerated regardless of CS etiology and severity.

Schlagwörter

Stichwörter der Autor:innen

Cushing diseaseadrenal Cushing syndromeectopic adrenocorticotropin syndromeosilodrostatreal worldretrospective

Autor:innen und Institutionen

  • Departments of Medicine and Neurological Surgery, Pituitary Center, Oregon Health & Science University, Portland, OR 97239, USA.
  • Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
  • Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109-2800, USA.
  • Department of Neuroendocrinology and Neurosurgery, Barrow Pituitary Center, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA.

ORCID-Profile: Maria Fleseriu, Richard J Auchus, Wenyu Huang, Cynthia Campos

Förderung

  • Recordati Rare Diseases
  • USA

Zitieren

APA

Fleseriu, M., Auchus, R. J., Huang, W., Spencer-Segal, J. L., Yuen, K. C. J., Dacus, K. C., Padgett, J., Babler, E. K., Das, A. K., Campos, C., Broder, M. S., & Ioachimescu, A. G. (2025). Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study. Journal of the Endocrine Society, 9(5). https://doi.org/10.1210/jendso/bvaf046

Vancouver

Fleseriu M, Auchus RJ, Huang W, Spencer-Segal JL, Yuen KCJ, Dacus KC, et al. Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study. Journal of the Endocrine Society. 2025;9(5). doi:10.1210/jendso/bvaf046

BibTeX
@article{Fleseriu2025,
  author = {Fleseriu, Maria and Auchus, Richard J and Huang, Wenyu and Spencer-Segal, Joanna L and Yuen, Kevin C J and Dacus, Kelley C and Padgett, Julianne and Babler, Elizabeth K and Das, Ashis K and Campos, Cynthia and Broder, Michael S and Ioachimescu, Adriana G},
  title = {Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study},
  journal = {Journal of the Endocrine Society},
  year = {2025},
  volume = {9},
  number = {5},
  doi = {10.1210/jendso/bvaf046}
}
Kostenlos starten →